United States Patent 8,956,288: Claim Scope, Expiration, Litigation Risk and Ingestible Sensor Patent Landscape
US Patent 8,956,288 protects an ingestible event marker that generates power from body fluids and transmits a signal through body tissue to a receiver. Its central technical limitation is a two-electrode battery in which one electrode uses a porous, surface-area-enhancing under-layer. The patent is directed to a device and communication architecture, not to a pharmaceutical active ingredient.
The broadest commercial risk is for ingestible sensors that combine: an integrated circuit, dissimilar electrode materials, a porous electrode under-layer, body-fluid activation, and galvanic body-tissue communication. A product using only a conventional battery, radiofrequency transmission, or a nonporous electrode structure would present a materially different infringement profile.
What does US Patent 8,956,288 protect?
The patent covers three related categories:
- A device containing the electrode-powered circuitry.
- A system combining the device with an in vivo or ex vivo receiver.
- Manufacturing and operational methods for producing and using the device.
The independent claims are Claims 1, 13, 16 and 17.
| Claim |
Category |
Principal subject matter |
| 1 |
Device |
Solid support, circuitry, two isolated electrodes, porous under-layer, body-fluid battery and tissue-conducted signal |
| 13 |
System |
Device of Claim 1 plus a receiver |
| 16 |
Method |
Emitting, receiving, ingesting or communicating with an ingestible event marker |
| 17 |
Manufacturing method |
Producing the porous first electrode and second electrode on a solid support |
The claim architecture is cumulative. An accused product must satisfy every limitation of an asserted claim, either literally or under the doctrine of equivalents. The patent does not broadly claim every ingestible sensor or every device that communicates through the body.
How does Claim 1 define the core invention?
Claim 1 contains the patent’s central combination:
- A solid support containing circuitry.
- A first electrode coupled to the circuitry.
- A porous under-layer beneath the first active electrode material.
- A second, electrically isolated electrode.
- Different active materials for the first and second electrodes.
- Activation when both materials contact conductive fluid within the body.
- Generation of a conductively transmitted signal using the body as the transmission medium.
The porous under-layer is a critical limitation. It must be selected to provide a surface-area enhancement to the first electrode. A merely rough, textured or conductive layer may not satisfy the limitation unless it functions as the claimed surface-area-enhancing under-layer.
The claim also requires that the first and second active electrode materials provide a voltage potential difference through completion of a battery. A product in which the electrodes merely act as antennas, capacitive sensors or passive contacts would not satisfy this limitation without a separate battery-generation theory.
What technical elements create the strongest infringement risk?
The highest-risk configuration is an ingestible tablet or capsule containing:
- A silicon or comparable circuit substrate.
- A pair of dissimilar metal electrodes.
- A porous metal layer beneath one active electrode.
- Gastrointestinal fluid as the electrolyte.
- A low-power circuit energized by the resulting voltage.
- Conductive transmission through the patient’s tissues to a receiver.
The patent is strongest when all of these elements are present in one integrated device. It is weaker against products that separate the power source from the communication electrodes, use wireless transmission, or omit the porous under-layer.
What dependent claims add to the patent scope?
Claims 2 through 12 narrow Claim 1 through specific structural and pharmaceutical configurations.
| Claims |
Added limitation |
| 2 |
Device is dimensioned to be ingestible |
| 3 |
Porous under-layer is conductive |
| 4 |
Under-layer includes Au, Cu, Pt, Ir, Pd, Rh, Ru or alloys |
| 5 |
Under-layer includes Ti, W or alloys |
| 6 |
Under-layer thickness is 0.1 to 100 micrometers |
| 7 |
Electrodes are on the same support surface |
| 8 |
Electrodes are on opposite support surfaces |
| 9 |
Pharmaceutically acceptable carrier composition |
| 10 |
Carrier is a tablet |
| 11 |
Carrier is a capsule |
| 12 |
Carrier includes an active agent |
Claims 4, 5 and 6 provide narrower fallback positions. They may be important during validity litigation because they impose measurable material and dimensional limitations. A product using a porous platinum, titanium or tungsten layer within the stated thickness range would face increased risk under those claims.
Claims 9 through 12 connect the electronics to a dosage form. They are commercially significant because they cover a sensor embedded in a tablet or capsule that also contains an active pharmaceutical agent.
What do Claims 13 through 15 protect?
Claim 13 covers a complete communication system. It requires the device architecture of Claim 1 and a receiver configured to communicate with the device.
Claims 14 and 15 divide the receiver into:
- An in vivo receiver under Claim 14.
- An ex vivo receiver under Claim 15.
This distinction gives the patent coverage across implanted or internal monitoring systems and external receivers worn on or carried by the patient. The receiver itself is not the primary inventive center of the claim. The asserted combination depends on the ingestible or body-activated device transmitting through body tissue.
A receiver manufacturer could face indirect or contributory infringement exposure if it supplies a receiver specifically configured for use with an infringing ingestible marker, although liability would depend on the full statutory and factual record.
What do Claims 16 through 20 protect?
Claim 16 is a use and operation claim. It covers at least one of:
- Emitting a conductively transmitted signal.
- Receiving such a signal.
- Ingesting the event marker.
- Communicating through the body as a conduction medium.
The claim incorporates the electrode, porous under-layer, battery and pharmaceutically acceptable carrier limitations. It is therefore narrower than a generic method of detecting ingestion.
Claim 17 covers manufacturing. It requires:
- Providing the porous under-layer.
- Depositing or providing the first active electrode material on that layer.
- Producing the second electrode with a different active material.
- Configuring the resulting device for body-conducted communication.
Claims 18 through 20 identify three methods for forming the porous under-layer:
- Electrodeposition.
- Cathodic arc deposition.
- Electrophoretic deposition.
These claims may be particularly relevant to contract manufacturers. A manufacturer could infringe the process claims even if the finished device is sold by another company, provided the claimed production steps are practiced in the United States.
When does US Patent 8,956,288 lose exclusivity?
The patent issued on February 17, 2015. Its term is governed by the 20-year period measured from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers and any applicable patent-term extension. The relevant statutory baseline appears to be in the early 2030s rather than 2035, because the patent’s term is not calculated from its issue date. [1]
| Event |
Date or timing |
| Patent grant |
February 17, 2015 |
| Ordinary patent term basis |
20 years from earliest effective nonprovisional filing |
| Expected baseline expiry |
Approximately 2032, subject to USPTO term calculation |
| Regulatory exclusivity |
Not created by this patent |
| Orange Book effect |
No direct Orange Book exclusivity for the device claims |
A precise expiration date requires the USPTO patent-term calculation, including any patent-term adjustment and terminal-disclaimer information. The patent should therefore be tracked by its USPTO maintenance and term records rather than by the 2015 grant date.
Is US Patent 8,956,288 an Orange Book drug patent?
No. The patent claims a powered ingestible device, a communication system and manufacturing methods. It does not claim aripiprazole, another active pharmaceutical ingredient, a pharmaceutical composition defined by drug chemistry, or a conventional drug treatment method.
The patent is therefore not, by its claim content, a typical Orange Book drug-substance or drug-product patent. It should not be used as the basis for assuming a Hatch-Waxman patent-barrier period for a generic drug.
This distinction matters for products such as Abilify MyCite. The FDA approved Abilify MyCite as a drug-device combination containing aripiprazole and an ingestible sensor system. FDA approval does not automatically make every patent covering the sensor an Orange Book-listed patent for aripiprazole. [2]
What FDA regulatory status is relevant?
The FDA approved Abilify MyCite in November 2017 as the first approved drug with a digital ingestion-tracking system. The product combined oral aripiprazole with an ingestible event marker and a wearable patch that detected the signal. [2]
The FDA labeling described the product as an aripiprazole tablet with an ingestible sensor, a wearable sensor patch and a smartphone application. The product was approved for selected indications already associated with oral aripiprazole, but the digital system did not establish improved adherence or improved clinical outcomes. [2]
US Patent 8,956,288 is technically relevant to this product category because its claims address:
- Ingestible dosage forms.
- Battery activation through gastrointestinal fluid.
- Conductive transmission through body tissues.
- Communication with external or internal receivers.
FDA approval, however, does not establish infringement. Patent scope and regulatory product descriptions must be compared limitation by limitation.
What formulation patents are relevant?
The formulation-related scope is concentrated in Claims 9 through 12. These claims cover a pharmaceutically acceptable carrier composition, including a tablet or capsule, and a composition containing an active agent.
The claims do not require a particular drug. They also do not require aripiprazole. A formulation containing another active agent could fall within the claims if the device includes the claimed electrode and communication architecture.
The commercial relevance is highest for:
- Digital tablets.
- Sensor-enabled capsules.
- Medication-adherence products.
- Ingestible event markers embedded in oral dosage forms.
- Combination products that transmit ingestion data to a wearable or mobile receiver.
The patent does not independently protect the formulation chemistry of a conventional tablet or capsule. The protected subject matter is the combination of the carrier with the electronic marker.
What method-of-use patents and manufacturing patents are covered?
Claim 16 is the principal method-of-use claim. It covers operation of the ingestible event marker and communication through the body. Its breadth is constrained by the incorporated device limitations.
Claims 17 through 20 are manufacturing claims. They may cover electrode fabrication even where the product is later incorporated into a pharmaceutical dosage form by a separate company.
The process limitations create several potential design-around routes:
- Use a nonporous first electrode.
- Create surface enhancement through the active electrode material itself rather than an under-layer.
- Use a porous layer formed by a method outside electrodeposition, cathodic arc deposition or electrophoretic deposition.
- Use a conventional internal battery.
- Use radiofrequency, magnetic, optical or acoustic transmission rather than body-conducted transmission.
A design-around must be assessed against all claims, not only Claims 18 through 20. Avoiding the three named fabrication methods does not avoid Claim 1 if the finished device still has the claimed porous under-layer.
How strong is the patent estate for this technology?
US 8,956,288 has meaningful commercial value but a technically concentrated claim set.
| Strength factor |
Assessment |
| Core commercial concept |
Strong coverage of body-fluid-powered ingestible communication |
| Porous electrode limitation |
Narrows scope but gives technical specificity |
| Pharmaceutical integration |
Claims 9-12 create dosage-form coverage |
| Receiver coverage |
Claims 13-15 extend protection to complete systems |
| Manufacturing coverage |
Claims 17-20 target electrode fabrication |
| Generic drug relevance |
Limited because the claims are not drug-chemical claims |
| Device-company relevance |
High for ingestible sensor manufacturers |
| Design-around exposure |
Material because the claims require specific power and transmission mechanisms |
| Invalidity exposure |
Potentially significant under obviousness and written-description theories |
The patent’s strongest feature is the combination of a high-surface-area electrode with a body-fluid-activated battery and conductively transmitted signal. Its principal weakness is that each element must be present in the claimed relationship. Prior art showing ingestible electronics, galvanic cells, porous electrodes or body-conducted communication separately could be combined in an obviousness challenge.
Potential validity issues include:
- Whether earlier ingestible event markers disclosed the same two-electrode battery architecture.
- Whether porous electrode layers and surface-area enhancement were routine electrochemical techniques.
- Whether the specification adequately supports the full range of claimed materials and thicknesses.
- Whether the claims clearly define the relationship between the porous under-layer and the active electrode material.
- Whether “conductively transmitted signal” provides sufficient structural and functional boundaries.
Which companies are most exposed to the patent landscape?
The highest exposure is concentrated among companies developing ingestible sensors rather than conventional generic-drug manufacturers.
| Company or category |
Relevance |
| Proteus Digital Health |
Historical developer and principal commercial source of the ingestible event-marker platform |
| Otsuka Pharmaceutical |
Commercialized Abilify MyCite with Proteus technology |
| Digital medicine developers |
Potential users of ingestible sensors and adherence platforms |
| Generic-drug companies |
Exposure mainly when reproducing a patented sensor-enabled dosage form |
| Medical-device manufacturers |
Exposure if supplying the ingestible marker, receiver or electrode assembly |
| Contract manufacturers |
Potential direct exposure to process claims 17-20 |
Proteus entered bankruptcy proceedings in 2020. Otsuka had been Proteus’s principal commercial partner for Abilify MyCite and subsequently pursued control or continuation of relevant digital-medicine assets and programs. The commercial history creates licensing and asset-chain importance, but patent ownership must be confirmed from current USPTO assignment records rather than inferred from historical commercial relationships. [3]
What Paragraph IV challenge risk exists?
A Paragraph IV certification is relevant to an ANDA applicant challenging patents listed for an approved drug product. Because US 8,956,288 is a device and system patent, it is not inherently an Orange Book barrier to a conventional generic aripiprazole product.
Paragraph IV exposure could arise if:
- The patent is listed against a drug-device combination product.
- A generic applicant seeks approval for a sensor-enabled version of the product.
- The FDA-listed patent record identifies the patent as relevant to the approved combination product.
- The ANDA applicant certifies that the patent is invalid, unenforceable or not infringed.
For a conventional aripiprazole tablet without the claimed ingestible electronics, the patent’s relevance is substantially lower. For a sensor-enabled generic version of Abilify MyCite, infringement analysis would focus on the porous electrode structure, dissimilar electrode materials, body-fluid battery and conductively transmitted signal.
No biosimilar pathway applies. Abilify MyCite contains a small-molecule active ingredient, not a biologic. The relevant competitive pathway is generic-drug and drug-device combination-product regulation, not biosimilar interchangeability.
What patent litigation and settlement issues affect the patent?
The patent document itself does not establish current litigation, licensing or settlement status. The principal legal risk is product-specific infringement analysis involving the Proteus ingestible event-marker portfolio, not ordinary generic competition against aripiprazole.
A diligence review should distinguish among:
- Ownership of US 8,956,288.
- Exclusive or field-limited licenses.
- Bankruptcy-related asset transfers.
- Patent litigation involving related Proteus patents.
- FDA-listed patents for Abilify MyCite.
- Settlements that may restrict launch dates or fields of use.
A settlement involving a related Proteus patent would not automatically resolve or exhaust rights under US 8,956,288 unless the agreement expressly covers this patent and the relevant products.
How does US 8,956,288 compare with competing technology approaches?
| Technology approach |
Likely position relative to US 8,956,288 |
| Porous dissimilar-metal electrodes activated by body fluid |
Highest overlap |
| Conventional miniature battery inside an ingestible capsule |
Lower overlap with battery-generation limitation |
| RF transmission from an ingestible device |
Lower overlap with body-conduction limitation |
| Passive RFID ingestible marker |
Lower overlap if no claimed battery-powered circuitry |
| Optical ingestion marker |
Generally outside the claimed electrical architecture |
| Magnetic or acoustic marker |
Generally outside the claimed conductive-signal architecture |
| Sensor-only tablet with no transmission circuit |
Outside the principal device claims |
| Conductive transmission using a nonporous electrode |
Potential design-around, subject to equivalents |
Geographic coverage is principally United States coverage. Foreign counterpart patents, continuation applications and national-phase filings may create parallel rights in Europe, Canada, Japan, Australia and other markets, but those rights require separate claim and term analysis. US 8,956,288 alone does not establish worldwide exclusivity.
Key Takeaways
- US 8,956,288 is a device and system patent, not a conventional drug patent.
- Its central claim requires a porous surface-area-enhancing under-layer beneath one active electrode.
- The device is powered when dissimilar electrode materials contact conductive body fluid.
- The resulting circuitry transmits a signal through body tissue to an in vivo or ex vivo receiver.
- Claims 9 through 12 extend coverage to tablets, capsules and active-agent formulations.
- Claims 17 through 20 target electrode manufacturing methods.
- The patent issued on February 17, 2015, but its term is calculated from the earliest effective nonprovisional filing date, with an expected baseline in approximately 2032.
- Conventional generic aripiprazole products face limited exposure because the claims are not directed to aripiprazole or ordinary tablets.
- Sensor-enabled generic products and ingestible-event-marker platforms face substantially greater risk.
- The main design-around strategies are a nonporous electrode, a separate conventional battery, or nonconductive wireless transmission.
- No biosimilar pathway applies because the underlying product is a small-molecule drug-device combination.
FAQs About US Patent 8,956,288
Does US Patent 8,956,288 cover Abilify MyCite?
It may be technically relevant to the ingestible sensor architecture used in Abilify MyCite, but coverage depends on whether the commercial product practices every limitation of an asserted claim.
Can a generic manufacturer sell ordinary aripiprazole tablets despite this patent?
The patent does not claim aripiprazole itself or an ordinary aripiprazole tablet. A conventional generic tablet without the claimed ingestible electronics would generally present a different infringement profile.
Does the patent cover every ingestible sensor?
No. The claims require a particular electrically activated architecture, including dissimilar electrode materials, a porous under-layer and body-conducted communication.
Is the porous under-layer required to be made from platinum or titanium?
No. Claims 4 and 5 identify specific material groups, but Claim 1 is broader and requires the porous surface-area-enhancing under-layer without limiting it to those materials.
Can a company avoid the patent by using radiofrequency transmission?
Radiofrequency transmission may avoid the body-conduction limitation, but the complete product and all asserted claims must be analyzed. A product could still implicate separate patents in the ingestible-sensor portfolio.
References
- United States Patent and Trademark Office. (2015). US Patent No. 8,956,288, Ingestible event marker with increased surface area electrode.
- U.S. Food and Drug Administration. (2017). FDA approves pill with sensor that digitally tracks if patients have ingested their medication.
- Otsuka Pharmaceutical Co., Ltd. (2017). FDA approves Abilify MyCite, the first digital medicine system.
